AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VALINE, LEUCINE AND ISOLEUCINE

Information current as at: 1 June 2026

PBAC meeting date: July 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • MSUD Anamix Infant®
  • MSUD Anamix Junior®
  • MSUD Lophlex LQ 20®
  • MSUD Maxamum®
Form and strength:
  • Oral powder 400 g (MSUD Anamix infant)
  • Sachets containing oral powder 36 g, 30 (MSUD Anamix Junior)
  • Oral liquid 125 mL, 30 (MSUD Lophlex LQ 20)
  • Oral powder 500 g (MSUD Maxamum)
Submission sponsor:
NUTRICIA AUSTRALIA PTY LTD
Condition/indication:
(therapeutic use)
  • Short-chain enoyl-CoA hydratase (ECHS1) deficiency
Listing requested:
To request listing of MSUD Anamix Infant, MSUD Anamix Junior, MSUD Lophlex LQ 20 and MSUD Maxamum for the dietary management of infants and children with ECHS1 deficiency (the same dietary management approach used in Maple Syrup Urine Disease (MSUD)).
Funding program:
PBS General Schedule
Request authority level:
Restricted Benefit
PBAC Submission type:
Change to existing listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2026 PBAC meeting
Opportunity for consumer comment:
Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
1205
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19